'Selective' COX-1 or COX-2 NSAIDs: time to change a misleading measure

'Selective' COX-1 or COX-2 NSAIDs: time to change a misleading measure

The ongoing important debate about the relative benefits/risks of COX‐1 or COX‐2 NSAIDs is hampered by the use of a measure of ‘selectivity’ that is inherently flawed. An alternative measure provides more meaningful and clinically relevant information.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical pharmacy and therapeutics 2014-10, Vol.39 (5), p.455-456
Hauptverfasser: Raffa, R. B., Gudin, J. A., Nalamachu, S., Pergolizzi Jr, J. V.
Format: Artikel
Sprache:eng
Schlagworte:
Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics
Confounding Factors (Epidemiology)
Cyclooxygenase 1 - metabolism
Cyclooxygenase 2 Inhibitors - metabolism
Cyclooxygenase Inhibitors - metabolism
Humans
Inhibitory Concentration 50
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 456
container_issue 5
container_start_page 455
container_title Journal of clinical pharmacy and therapeutics
container_volume 39
creator Raffa, R. B.
Gudin, J. A.
Nalamachu, S.
Pergolizzi Jr, J. V.
description The ongoing important debate about the relative benefits/risks of COX‐1 or COX‐2 NSAIDs is hampered by the use of a measure of ‘selectivity’ that is inherently flawed. An alternative measure provides more meaningful and clinically relevant information.
doi_str_mv 10.1111/jcpt.12192
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1558516835</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1558516835</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4642-781d533f8028fe4b98296822e941e5c0e0ead5b5ae4b1f76a5cb03c3e71ffa273</originalsourceid><addsrcrecordid>eNp9kEtLw0AQxxdRtD4ufgBZ8FARovvMJt5Ka30grVBFb8t2O9HUpKm7iY9v77ZVDx6cywzMb34Mf4T2KTmhoU6ndl6fUEZTtoZalMcyYoqSddQiLE4joZjaQtveTwkhsWJ8E20xSRQRadJC_fYICrB1_gZt3B0-RhRXbjkwPBh1rnr-DNd5CbiusH02syfABpe5L8BM8tkTLsH4xsEu2shM4WHvu--g-_75XfcyuhleXHU7N5EVsWCRSuhEcp4lhCUZiHGasDROGINUUJCWAAlaOZYm7GimYiPtmHDLQdEsM0zxHXS08s5d9dqAr3X4xUJRmBlUjddUykTSOOEyoId_0GnVuFn4bkEpokSa8kAdryjrKu8dZHru8tK4T02JXqSrF-nqZboBPvhWNuMSJr_oT5wBoCvgPS_g8x-Vvu7e3v1Io9VN7mv4-L0x7kXHiiupHwYX-rJ_qwZC9PSIfwHvIo-U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1557074993</pqid></control><display><type>article</type><title>'Selective' COX-1 or COX-2 NSAIDs: time to change a misleading measure</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Raffa, R. B. ; Gudin, J. A. ; Nalamachu, S. ; Pergolizzi Jr, J. V.</creator><creatorcontrib>Raffa, R. B. ; Gudin, J. A. ; Nalamachu, S. ; Pergolizzi Jr, J. V.</creatorcontrib><description>The ongoing important debate about the relative benefits/risks of COX‐1 or COX‐2 NSAIDs is hampered by the use of a measure of ‘selectivity’ that is inherently flawed. An alternative measure provides more meaningful and clinically relevant information.</description><identifier>ISSN: 0269-4727</identifier><identifier>EISSN: 1365-2710</identifier><identifier>DOI: 10.1111/jcpt.12192</identifier><identifier>PMID: 25070498</identifier><identifier>CODEN: JCPTED</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics ; Confounding Factors (Epidemiology) ; Cyclooxygenase 1 - metabolism ; Cyclooxygenase 2 Inhibitors - metabolism ; Cyclooxygenase Inhibitors - metabolism ; Humans ; Inhibitory Concentration 50</subject><ispartof>Journal of clinical pharmacy and therapeutics, 2014-10, Vol.39 (5), p.455-456</ispartof><rights>2014 John Wiley &amp; Sons Ltd</rights><rights>2014 John Wiley &amp; Sons Ltd.</rights><rights>Copyright © 2014 John Wiley &amp; Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4642-781d533f8028fe4b98296822e941e5c0e0ead5b5ae4b1f76a5cb03c3e71ffa273</citedby><cites>FETCH-LOGICAL-c4642-781d533f8028fe4b98296822e941e5c0e0ead5b5ae4b1f76a5cb03c3e71ffa273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjcpt.12192$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjcpt.12192$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25070498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raffa, R. B.</creatorcontrib><creatorcontrib>Gudin, J. A.</creatorcontrib><creatorcontrib>Nalamachu, S.</creatorcontrib><creatorcontrib>Pergolizzi Jr, J. V.</creatorcontrib><title>'Selective' COX-1 or COX-2 NSAIDs: time to change a misleading measure</title><title>Journal of clinical pharmacy and therapeutics</title><addtitle>J Clin Pharm Ther</addtitle><description>The ongoing important debate about the relative benefits/risks of COX‐1 or COX‐2 NSAIDs is hampered by the use of a measure of ‘selectivity’ that is inherently flawed. An alternative measure provides more meaningful and clinically relevant information.</description><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics</subject><subject>Confounding Factors (Epidemiology)</subject><subject>Cyclooxygenase 1 - metabolism</subject><subject>Cyclooxygenase 2 Inhibitors - metabolism</subject><subject>Cyclooxygenase Inhibitors - metabolism</subject><subject>Humans</subject><subject>Inhibitory Concentration 50</subject><issn>0269-4727</issn><issn>1365-2710</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLw0AQxxdRtD4ufgBZ8FARovvMJt5Ka30grVBFb8t2O9HUpKm7iY9v77ZVDx6cywzMb34Mf4T2KTmhoU6ndl6fUEZTtoZalMcyYoqSddQiLE4joZjaQtveTwkhsWJ8E20xSRQRadJC_fYICrB1_gZt3B0-RhRXbjkwPBh1rnr-DNd5CbiusH02syfABpe5L8BM8tkTLsH4xsEu2shM4WHvu--g-_75XfcyuhleXHU7N5EVsWCRSuhEcp4lhCUZiHGasDROGINUUJCWAAlaOZYm7GimYiPtmHDLQdEsM0zxHXS08s5d9dqAr3X4xUJRmBlUjddUykTSOOEyoId_0GnVuFn4bkEpokSa8kAdryjrKu8dZHru8tK4T02JXqSrF-nqZboBPvhWNuMSJr_oT5wBoCvgPS_g8x-Vvu7e3v1Io9VN7mv4-L0x7kXHiiupHwYX-rJ_qwZC9PSIfwHvIo-U</recordid><startdate>201410</startdate><enddate>201410</enddate><creator>Raffa, R. B.</creator><creator>Gudin, J. A.</creator><creator>Nalamachu, S.</creator><creator>Pergolizzi Jr, J. V.</creator><general>Blackwell Publishing Ltd</general><general>Hindawi Limited</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>201410</creationdate><title>'Selective' COX-1 or COX-2 NSAIDs: time to change a misleading measure</title><author>Raffa, R. B. ; Gudin, J. A. ; Nalamachu, S. ; Pergolizzi Jr, J. V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4642-781d533f8028fe4b98296822e941e5c0e0ead5b5ae4b1f76a5cb03c3e71ffa273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics</topic><topic>Confounding Factors (Epidemiology)</topic><topic>Cyclooxygenase 1 - metabolism</topic><topic>Cyclooxygenase 2 Inhibitors - metabolism</topic><topic>Cyclooxygenase Inhibitors - metabolism</topic><topic>Humans</topic><topic>Inhibitory Concentration 50</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raffa, R. B.</creatorcontrib><creatorcontrib>Gudin, J. A.</creatorcontrib><creatorcontrib>Nalamachu, S.</creatorcontrib><creatorcontrib>Pergolizzi Jr, J. V.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pharmacy and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raffa, R. B.</au><au>Gudin, J. A.</au><au>Nalamachu, S.</au><au>Pergolizzi Jr, J. V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>'Selective' COX-1 or COX-2 NSAIDs: time to change a misleading measure</atitle><jtitle>Journal of clinical pharmacy and therapeutics</jtitle><addtitle>J Clin Pharm Ther</addtitle><date>2014-10</date><risdate>2014</risdate><volume>39</volume><issue>5</issue><spage>455</spage><epage>456</epage><pages>455-456</pages><issn>0269-4727</issn><eissn>1365-2710</eissn><coden>JCPTED</coden><abstract>The ongoing important debate about the relative benefits/risks of COX‐1 or COX‐2 NSAIDs is hampered by the use of a measure of ‘selectivity’ that is inherently flawed. An alternative measure provides more meaningful and clinically relevant information.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>25070498</pmid><doi>10.1111/jcpt.12192</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0269-4727
ispartof Journal of clinical pharmacy and therapeutics, 2014-10, Vol.39 (5), p.455-456
issn 0269-4727
1365-2710
language eng
recordid cdi_proquest_miscellaneous_1558516835
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics
Confounding Factors (Epidemiology)
Cyclooxygenase 1 - metabolism
Cyclooxygenase 2 Inhibitors - metabolism
Cyclooxygenase Inhibitors - metabolism
Humans
Inhibitory Concentration 50
title 'Selective' COX-1 or COX-2 NSAIDs: time to change a misleading measure
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T17%3A32%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle='Selective'%20COX-1%20or%20COX-2%20NSAIDs:%20time%20to%20change%20a%20misleading%20measure&rft.jtitle=Journal%20of%20clinical%20pharmacy%20and%20therapeutics&rft.au=Raffa,%20R.%20B.&rft.date=2014-10&rft.volume=39&rft.issue=5&rft.spage=455&rft.epage=456&rft.pages=455-456&rft.issn=0269-4727&rft.eissn=1365-2710&rft.coden=JCPTED&rft_id=info:doi/10.1111/jcpt.12192&rft_dat=%3Cproquest_cross%3E1558516835%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1557074993&rft_id=info:pmid/25070498&rfr_iscdi=true